GB2124614A - Easily cleavable carboxylic esters and their use in the synthesis of penems and other b-lactam antibiotics - Google Patents
Easily cleavable carboxylic esters and their use in the synthesis of penems and other b-lactam antibiotics Download PDFInfo
- Publication number
- GB2124614A GB2124614A GB08314782A GB8314782A GB2124614A GB 2124614 A GB2124614 A GB 2124614A GB 08314782 A GB08314782 A GB 08314782A GB 8314782 A GB8314782 A GB 8314782A GB 2124614 A GB2124614 A GB 2124614A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formula
- compound
- acid
- symbol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003782 beta lactam antibiotic agent Substances 0.000 title description 6
- 150000002961 penems Chemical class 0.000 title description 4
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- -1 formyl phenyl Chemical group 0.000 claims abstract description 83
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000002253 acid Substances 0.000 claims abstract description 28
- 150000002148 esters Chemical class 0.000 claims abstract description 27
- 125000001424 substituent group Chemical group 0.000 claims abstract description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001301 oxygen Substances 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 15
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 11
- 150000002367 halogens Chemical group 0.000 claims abstract description 11
- 125000000962 organic group Chemical group 0.000 claims abstract description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005864 Sulphur Chemical group 0.000 claims abstract description 8
- 125000004442 acylamino group Chemical group 0.000 claims abstract description 8
- 125000003118 aryl group Chemical group 0.000 claims abstract description 8
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002619 bicyclic group Chemical group 0.000 claims abstract description 7
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 7
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 5
- 230000003115 biocidal effect Effects 0.000 claims abstract description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims abstract description 3
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 43
- 230000008569 process Effects 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 239000000460 chlorine Chemical group 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 14
- 150000003254 radicals Chemical group 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- 238000003776 cleavage reaction Methods 0.000 claims description 10
- 230000007017 scission Effects 0.000 claims description 10
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 claims description 8
- 150000004820 halides Chemical class 0.000 claims description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 7
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000000468 ketone group Chemical group 0.000 claims description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 239000001358 L(+)-tartaric acid Substances 0.000 claims description 3
- 235000011002 L(+)-tartaric acid Nutrition 0.000 claims description 3
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 150000007517 lewis acids Chemical class 0.000 claims description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims description 2
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical compound BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000002373 hemiacetals Chemical class 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 150000007513 acids Chemical class 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 28
- 239000000047 product Substances 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000002904 solvent Substances 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- QOEUNLQGZBSTBB-UHFFFAOYSA-N 1-methylazetidin-2-one Chemical compound CN1CCC1=O QOEUNLQGZBSTBB-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 6
- 150000001735 carboxylic acids Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 238000010626 work up procedure Methods 0.000 description 5
- RKPYPVYWRWYHKC-WPZCJLIBSA-N (6r)-3-methyl-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound C1([C@@H]2N(C1=O)C(=C(CS2)C)C(O)=O)NC(=O)COC1=CC=CC=C1 RKPYPVYWRWYHKC-WPZCJLIBSA-N 0.000 description 4
- GAGMGUXDWOWEJK-UHFFFAOYSA-N 1-chloroethoxybenzene Chemical compound CC(Cl)OC1=CC=CC=C1 GAGMGUXDWOWEJK-UHFFFAOYSA-N 0.000 description 4
- 125000006519 CCH3 Chemical group 0.000 description 4
- 229930186147 Cephalosporin Natural products 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 229940124587 cephalosporin Drugs 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- NPYBRLQTDJLRDQ-XXLUKPGQSA-N 1-phenoxyethyl (6R)-3-methyl-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound O(C1=CC=CC=C1)CC(=O)NC1[C@@H]2N(C(=C(CS2)C)C(=O)OC(C)OC2=CC=CC=C2)C1=O NPYBRLQTDJLRDQ-XXLUKPGQSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003396 thiol group Chemical class [H]S* 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- PUMIROZLQVCNOZ-BQYQJAHWSA-N (E)-4-oxo-4-(1-phenoxyethoxy)but-2-enoic acid Chemical compound OC(=O)/C=C/C(=O)OC(C)OC1=CC=CC=C1 PUMIROZLQVCNOZ-BQYQJAHWSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LEJJHHKNWKNKRW-PUKAKQIMSA-N 1-(4-nitrophenoxy)ethyl (6R)-3-methyl-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [N+](=O)([O-])C1=CC=C(OC(C)OC(=O)C2=C(CS[C@H]3N2C(C3NC(COC2=CC=CC=C2)=O)=O)C)C=C1 LEJJHHKNWKNKRW-PUKAKQIMSA-N 0.000 description 2
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 2
- XTVUXNLJQRWUBD-UHFFFAOYSA-N 1-ethenoxy-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OC=C)C=C1 XTVUXNLJQRWUBD-UHFFFAOYSA-N 0.000 description 2
- QKDCELCDMWTBSW-UHFFFAOYSA-N 1-phenoxyethyl 2-oxoacetate Chemical compound O=CC(=O)OC(C)OC1=CC=CC=C1 QKDCELCDMWTBSW-UHFFFAOYSA-N 0.000 description 2
- BYODIRBQCLALHQ-UHFFFAOYSA-N 1-phenoxyethyl 2-oxoacetate hydrate Chemical compound O.C(C=O)(=O)OC(C)OC1=CC=CC=C1 BYODIRBQCLALHQ-UHFFFAOYSA-N 0.000 description 2
- KVBUDNJPBTUZGW-UHFFFAOYSA-N 2,3-dihydroxy-4-oxo-4-(1-phenoxyethoxy)butanoic acid Chemical compound CC(OC1=CC=CC=C1)OC(=O)C(C(C(=O)O)O)O KVBUDNJPBTUZGW-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- CICCKONLHJXVNR-UHFFFAOYSA-N 2-(1-methyltetrazol-5-yl)ethanethioic s-acid Chemical compound CN1N=NN=C1CC(O)=S CICCKONLHJXVNR-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000007848 Bronsted acid Substances 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 2
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 229920001567 vinyl ester resin Polymers 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- MHSGOABISYIYKP-UHFFFAOYSA-N (4-nitrophenyl)methyl carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(COC(Cl)=O)C=C1 MHSGOABISYIYKP-UHFFFAOYSA-N 0.000 description 1
- UOUJHHNRTZZABP-ZCFIWIBFSA-N (5r)-3-methyl-4-thia-1-azabicyclo[3.2.0]hept-2-en-7-one Chemical compound S1C(C)=CN2C(=O)C[C@H]21 UOUJHHNRTZZABP-ZCFIWIBFSA-N 0.000 description 1
- YFGCWTCIFQHVBI-FQNRMIAFSA-N (6R)-3-ethyl-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O(C1=CC=CC=C1)CC(=O)NC1[C@@H]2N(C(=C(CS2)CC)C(=O)O)C1=O YFGCWTCIFQHVBI-FQNRMIAFSA-N 0.000 description 1
- KYUTYGAHECGMSX-RXMQYKEDSA-N (6r)-4,5-dithia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical compound S1SC=CN2C(=O)C[C@H]21 KYUTYGAHECGMSX-RXMQYKEDSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004755 (C2-C7) acylamino group Chemical group 0.000 description 1
- JYUXDXWXTPSAEL-UHFFFAOYSA-N 1,4-dioxane;oxolane Chemical compound C1CCOC1.C1COCCO1 JYUXDXWXTPSAEL-UHFFFAOYSA-N 0.000 description 1
- DVGOWCGSPNOJKN-UHFFFAOYSA-N 1-(1-chloroethenoxy)-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=C)C=C1 DVGOWCGSPNOJKN-UHFFFAOYSA-N 0.000 description 1
- ZPQDCRXASHORFN-PUKAKQIMSA-N 1-(4-chlorophenoxy)ethyl (6R)-3-methyl-8-oxo-7-[(2-phenoxyacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound O(C1=CC=CC=C1)CC(=O)NC1[C@@H]2N(C(=C(CS2)C)C(=O)OC(C)OC2=CC=C(C=C2)Cl)C1=O ZPQDCRXASHORFN-PUKAKQIMSA-N 0.000 description 1
- VQZGQTSSDVJEKF-UHFFFAOYSA-N 1-chloro-4-(1-chloroethoxy)benzene Chemical compound CC(Cl)OC1=CC=C(Cl)C=C1 VQZGQTSSDVJEKF-UHFFFAOYSA-N 0.000 description 1
- HDULJDRDAYLILV-UHFFFAOYSA-N 1-chloro-4-ethenoxybenzene Chemical compound ClC1=CC=C(OC=C)C=C1 HDULJDRDAYLILV-UHFFFAOYSA-N 0.000 description 1
- PEBJBOQKIXHSOE-UHFFFAOYSA-N 1-ethenoxy-4-methoxybenzene Chemical compound COC1=CC=C(OC=C)C=C1 PEBJBOQKIXHSOE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KPTNUCBVMWICQI-UHFFFAOYSA-N 1-methyl-2h-tetrazole-5-thione;sodium Chemical compound [Na].CN1NN=NC1=S KPTNUCBVMWICQI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GGHAOSLSOCDKQF-UHFFFAOYSA-N 2-[(4-nitrophenyl)methoxycarbonyloxy]acetic acid Chemical compound OC(=O)COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 GGHAOSLSOCDKQF-UHFFFAOYSA-N 0.000 description 1
- DEZBBPJAOPLLBJ-UHFFFAOYSA-N 2-[(4-nitrophenyl)methoxycarbonyloxy]ethanethioic s-acid Chemical compound [O-][N+](=O)C1=CC=C(COC(=O)OCC(S)=O)C=C1 DEZBBPJAOPLLBJ-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- DNGAFSPFLUNKSC-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(C=C1)C=COC=CC1=CC=C(C=C1)C(C)(C)C Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C=COC=CC1=CC=C(C=C1)C(C)(C)C DNGAFSPFLUNKSC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010056523 Hepatobiliary infection Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229910004809 Na2 SO4 Inorganic materials 0.000 description 1
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VHOMYEKCMUWHJI-VDTYLAMSSA-N [(2s,3s)-3-ethyl-4-oxoazetidin-2-yl] acetate Chemical compound CC[C@H]1[C@H](OC(C)=O)NC1=O VHOMYEKCMUWHJI-VDTYLAMSSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- UQDAEORWFCPQCU-UHFFFAOYSA-N acetic acid;oxolane;hydrate Chemical compound O.CC(O)=O.C1CCOC1 UQDAEORWFCPQCU-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- NHOGGUYTANYCGQ-UHFFFAOYSA-N ethenoxybenzene Chemical compound C=COC1=CC=CC=C1 NHOGGUYTANYCGQ-UHFFFAOYSA-N 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- WSHJJCPTKWSMRR-RXMQYKEDSA-N penam Chemical compound S1CCN2C(=O)C[C@H]21 WSHJJCPTKWSMRR-RXMQYKEDSA-N 0.000 description 1
- 125000002217 penem group Chemical group 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- CURNJKLCYZZBNJ-UHFFFAOYSA-M sodium;4-nitrophenolate Chemical compound [Na+].[O-]C1=CC=C([N+]([O-])=O)C=C1 CURNJKLCYZZBNJ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Compounds of formula <IMAGE> wherein R1 is hydrogen, halogen or an organic group; R2 and R3, being the same or different, are hydrogen or an organic group; R4 is an aromatic or heteroaromatic, monocyclic or bicyclic ring, unsubstituted or substituted by one or more substituents chosen from: C1- C6 alkyl, C1-C6 alkoxy, formyl phenyl, phenoxy, C2-C6 alkanoyl, benzoyl, C1-6 alkoxycarbonyl, amino optionally substituted by one or two C1-C6 alkyl, formylamino, C2-C6 acylamino, benzoyl-amino, halogen and nitro; the symbol -E- represents -O-; -S- or -CH2-; X is oxygen or sulphur; and the symbol ---Y) represents a group completing, with the group -E- and the fused azetidinone ring, the skeleton of a b-lactam antibiotic; and the salts thereof. These esters can be readily hydrolysed to the corresponding free acids which have a broad spectrum anti-bacterial activity.
Description
SPECIFICATION
Easily cleavable carboxylic esters and their use in the synthesis of penems and other p-lactam antibiotics
The present invention relates to new carboxylic esters of /3-lactam antibiotics, to a process for their preparation and to certain useful intermediates of the said process.
The compounds of this invention have the general formula (I)
wherein
R, is hydrogen, halogen or an organic group;
R2 and R3, being the same or different, are hydrogen or an organic group;
R4 is an aromatic or heteroaromatic, monocyclic or bicyclic ring, unsubstituted or substituted by one or more substituents chosen from: C1-C6 alkyl, C1-C6 alkoxy, formyl, phenyl, phenoxy, C2-C8 alkanoyl, benzoyl, C1-C6 alkoxycarbonyl, amino unsubstituted or substituted by one or two C1-C6 alkyl, formylamino, C2-C6 acylamino, benzoylamino, halogen and nitro;
the symbol -E- represents -0-; -S-or -CH2-; X is oxygen or sulphur; and
the symbol - - - YJ represents a group completing, with the group -E- and the fused azetidinone ring, the skeleton of a -lactam antibiotic. The scope of the invention includes also the salts and all the possible isomers of the compounds of formula (I), e.g. geometrical and optical isomers, and the mixtures thereof.
The alkyl, alkoxy, alkanoyl, alkoxycarbonyl, alkylamino and acylamino groups may be branched or straight chain groups. A halogen atom is for example chlorine, bromine or fluorine. An aromatic or heteroaromatic, monocyclic or bicyclic ring when substituted is preferably substituted by 1 to 3 substituents.
When R, is halogen, it is preferably chlorine, bromine or iodine.
When R, is an organic group, it is, for example, an acylamino group, a free or protected amino group or a substituted or unsubstituted aliphatic hydrocarbon groups. In particular, when R, is an acylamino group, it is preferably a substituted C2C8 alkanoylamino group, in particular a substituted acetylamino group, still preferably a) an arylacetamido group, in which the term aryl stands for an aromatic homocyclic or heterocyclic radical, unsubstituted or substituted by one or more substituents chosen from C1-C12 alkyl, halogen, hydroxy and amino; or b) a phenoxyacetamido group; or c) a 2aryl-2-methoxyiminoacetmido group, wherein the term aryl stands, preferably, for phenyl, 2-furyl, 2thienyl or 2-aminothiazol-4-yl.
When R, is a protected amino group, it is, for example, a straight or branched C,--C, alkoxycarbonylamino group, e.g., tert-butoxycarbonylamino; or it is an imine, preferably a Schiff base with an aromatic aldehyde; or it is a C2-C6 substituted or unsubstituted acylamino, or a formylamino group; still preferably it is formylamino, acetamido and chloroacetamido.
When R, is a substituted or unsubstituted aliphatic hydrocarbon group, it is, e.g., a radical chosen from C1-C12 alkyl and C4-C7 cycloalkyl, wherein said radical is unsubstituted or substituted by one or more substituents chosen from hydroxy, amino, cyano and mercapto and in which the hydroxy, amino and mercapto groups can be free or in a protected form; preferred protecting groups for amino, hydroxy and mercapto groups are those known from the chemistry of peptides and i3-lactam antibiotics. When
R1 is a substituted or unsubstituted aliphatic hydrocarbon group, it is preferably ethyl or 1-hydroxyethyl.
When R2 and/or R3 is an organic group, it is for example C1-C6 alkyl, preferably C,--C, alkyl. R2 and R3, being the same or different, are preferably hydrogen or methyl.
When R4 is an aromatic monocyclic ring, it is, e.g. phenyl unsubstituted or substituted by one or more substituents chosen from C1-C6 alkyl, preferably methyl and tert-butyl; amino; nitro; halogen, preferably chlorine; trihalo-C1-C6 alkyl, preferably trifluoromethyl; C1-C4 alkoxycarbonyl, preferably -COOCH3 and -CO0C2H5; C2-C6 alkanoyl, preferably acetyl; C2-C7 acylamino, preferably acetylamino; and C1-C6alkoxy.
When R4 is a hetero-aromatic monocyclic ring, it is preferably pyridine.
When R4 is a bicyclic ring, it is preferably quinoline. The skeleton of the p-lactam antibiotic referred to above is preferably the skeleton of a penicillin, a cephalosporin, a penem, a carbapenem or a 1 -oxa-l -dethiacephalosporin. Preferably E is --OO- or --SS-, especially -S-. Preferably the symbol --- Y & is a group chosen from:
wherein R5 is hydrogen or an organic group; more preferably it is the
group, which completes with the fused azetidinone ring and the -E- group, when -S-, -a penem nucleus.
When R5 is an organic group, it is, e.g., an unsubstituted or substituted C1-C4 alkyl group, preferably a methyl group unsubstituted or substituted by a substituent chosen from
a') halogen, e.g., chlorine or bromine;
b') an acyloxy group, e.g. a C2-C9 alkanoyloxy group, in particular acetoxy;
c') a carbamoyloxy group unsubstituted or substituted by one or two substituents chosen from C1-C4 alkyl and phenyl; and
d') a -5-Het group, wherein Het denotes a saturated or unsaturated, heteromonocyclic or heterobicyclic ring, containing one or more heteroatoms chosen from nitrogen, oxygen and sulphur.
Said ring is, preferably, chosen from the group consisting of thiazole, thiadiazole, tetrazole, triazine and tetrazolo-pyridazine, and is in turn unsubstituted or substituted by one or more substituents chosen, e.g., from cyano; C1-C12 alkyl, preferably C1-C4 alkyl; hydroxy; amino; halogen, preferably chlorine; C1-C12 alkoxy, preferably C1-C4 alkoxy; formyloxy; C2-C12 acyloxy; carboxy; C1-C12 alkoxycarbonyl and carbamoyl unsubstituted or substituted by one or two C1-C4 alkyl group.
Preferred compounds of formula (I) are those wherein:
R, is hydrogen, chlorine, bromine, amino, phenylacetamido, phenoxyacetamido, 2-amino-2phenyl-acetamido, 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido, C1-C4 alkyl or 1-hydroxyethyl; R2 and3, being the same or different, are hydrogen or C1-C6 alkyl;
R4 is phenyl, unsubstituted or substituted by 1, 2 or 3 substituents chosen from chlorine, nitro, methoxy, C1-C4 alkyl, amino, formamido, C2-C3 alkanoylamino;
X is oxygen; the symbol -E- represents -S-or -0-, wherein, when the symbol -E represents-S-, the symbol ~ - YJ represents a group chosen from:
wherein R5 is as defined above and wherein, when the symbol -E- represents -0-, then the symbol # Y# represents
wherein R5 is as defined above; and the salts thereof.
More preferred compounds of formula (I) are those wherein:
R, is hydrogen, chlorine, bromine, amino, phenylacetamido, phenoxyacetamido, 2-amino-2phenyl-acetamido, 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido, alkyl alkyl or 1-hydroxyethyl;
R2 and R3 are hydrogen;
R4 is phenyl, p-nitrophenyl, p-aminophenyl, p-chlorophenyl, p-tolyl, p-tert-butylphenyl, pacetamidophenyl;
X is oxygen; the symbol E represents -S-or -0-, wherein, when the symbol -E represents-S-, the symbol -- YJ represents a group chosen from:
and wherein, when the symbol -E- represents -0-, the symbol - - Y represents
wherein in both the cases R5 is C1-C4 alkyl unsubstituted or substituted by a substituent chosen from::
a") chlorine or bromine;
b") a C2-C9 alkanoyloxy group;
c") a carbamoyloxy group unsubstituted or substituted by one or two substituents chosen from C1-C4 alkyl and phenyl, and d") a -S-Het group, wherein Het denotes a heteromonocyclic or heterobicyclic ring chosen from the group consisting of thiazole, thiadiazole, tetrazole, triazine and tetrazolopyridazine, wherein said ring is in turn unsubstituted or substituted by 1, 2 or 3 substituents chosen from cyano, C1-C12 alkyl, amino, bromine, chlorine, hydroxy, C1-C12 alkoxy, formyloxy, C2-C12 acyloxy, carboxy, C1-C12 alkoxycarbonyl, and carbamoyi unsubstituted or substituted by one or two C1-C4 alkyl groups;and the salts thereof.
Particularly preferred compounds of formula (I) are those wherein:
R, is ethyl or 1-hydroxyethyl; R2 and R3 are hydrogen;
R4 is phenyl, p-nitrophenyl, p-aminophenyl, p-chlorophenyl; X is oxygen;
the symbol -E- is sulphur;
the symbol --- YJ is a group
wherein R5 is acetoxymethyl, carbamoyloxymethyl, (1 -methyl- 1 ,2,3,4-tetrazol-5-yl)-thiomethyl, (1 carboxymethyl-1 ,2,3,4-tetrazol-5-yl)-thiomethyl, [ 1 -(2-carboxy)ethyl- 1 ,2,3,4-tetrazol-5-yl]-thiomethyl, 2-(2-methyl-5-oxo-6-hydroxy-2,5-dihydro- 1 ,2,4-triazin-3-yl)-thiomethyl, [1 -(2-dimethylamino)-ethyl- 1 ,2,3,4-tetrazol-5-yl]-thiomethyl, and the salts thereof.
Salts of the compounds of formula (I) include acid addition salts either with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric, acids, or organic, e.g. acetic propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic, acids as well as salts either with inorganic, e.g. alkali metal, especially sodium or potassium bases, or alkaline-earth metal, especially calcium or magnesium bases, or with organic bases, e.g.
alkylamines, preferably triethylamine.
It is well known that the removal of a conventional carboxy protecting group from a p-lactam derivative, especially from a bicyclic one, may be a critical reaction. The choice of a suitable ester, i.e.
an ester which can safely survive through a multistep process, yet being readily cleaved at its end, is often the crucial factor in the success of a synthetic pathway leading to a compound of formula (I), no matter how trivial the former and how fascinating the latter may look; hence the constant need for new carboxy protecting groups in the chemistry of p-lactam antibiotics.
The esters of formula (I) and the salts thereof provide a new family of carboxy protecting groups, generally cleavable under the mild conditions required for the survival of the sensitive p-lactam moiety, with the additional advantage that the desired degree of reactivity can be modulated by the choice of the substituent(s) on the R4 ring. More specifically, electron-withdrawing substituents (e.g., R4=pnitrophenyl) provide increased stability towards acid hydrolysis, while electron-donating substituents (e.g., R4=p-methoxyphenyl) lessen the stability of esters (II) in comparison with the basic entry (R4=phenyl).
The main advantage offered by the esters of formula (I) and salts thereof over the conventional carboxy protecting groups known in the literature and under current use, as benzyl, p-nitrobenzyl, tertbutyl, diphenylmethyl or the like, lies in the mildness of the conditions needed for their cleavage.
Moreover, most of them are resistant to ozonolysis and cold aqueous permanganate, unlike, e.g.
allyl esters, and the a-phosphoranylidene derivatives thereof can readily undergo an internal Wittig reaction with a thioester carbonyl of the type described by Woodward et al., J. Am. Chem. Soc., 100, 8214, 1978, unlike, e.g., trichloroethyl esters.
An eloquent example is offered by the synthesis of (5R,6S)-6-ethyl-2-( 1 -methyl-1 ,2,3,4-tetrazol5-yl)-thiomethyl-penem-3-carboxylic acid, which we were unable to achieve by catalytic hydrogenation of its benzyl or p-nitrobenzyl ester (reduction to the 2-methylpenem occuring instead), or by titration of its acetonyl ester with 0.1 N NaOH (migration of the penem double bond to the exocyclic position), or by trifluoroacetic acid-or trimethylsilyliodide-mediated hydrolysis of its tertbutylester (loss of the ,B-lactam moiety). Eventually, said product was obtained in high yield, according to the present invention by extremely mild acid hydrolysis of its 1 -phenoxyethylester, i.e. by simple exposure to aqueous acetic acid or even by stirring with an aqueous solution of sodium metabisulphite.
Another advantage offered by the esters of formula (I) and salts thereof, due to their possibility to survive through various processes yet being readily cleaved at their end, is their use in processes concerning the interconversion between compounds of formula (I), which otherwise should not be possible or convenient to carry out on the corresponding free acids.
An additional advantage offered by the use of said esters and salts thereof is the easiness of the esterification of their carboxylic acid precursors, which does not require any activation step, such as their prior conversion into acyl halides. Another advantage over some of the known reagents used in the protection of carboxylic acids is their low cost, as the preparation (vide infra) of most of the esters of formula (I) can be achieved in bulk starting from extremely cheap materials, such as acetylene, phenol and hydrogen chloride.As is known, the free acids deriving from the cleavage of the esters of formula (I) have a high antibacterial activity both in animals and in humans against gram-positive and gram-negative bacteria such as straphylococci, streptococci, diplococci, Kleibsiella, Escherichia coli,
Proteus, mirabilis, Salmonella, Shigella, Haemophilus and Neisseria. They show also a high activity against the strong betalactamase producer microorganisms, such as, for example, Klebsiella aerogenes 1082 E, Escherichia coli Tern, Enterobacter cloacae P 99, and indole-positive Proteus and the like, as well as against Pseudomonas aeruginosa strains. The said free acids and the pharmaceutically acceptable salts thereof are therefore useful in human therapy and in veterinary.
The compounds of formula (I) can be prepared by a process comprising:
A) joining a synthon of formula (II)
wherein
R6 is a radical deriving from an a-aminoacid, an a-hydroxyacid, an a-ketoacid, or an a-alkenoic acid, wherein the amino, hydroxy and keto groups are either free or protected with a protective group in current use in the field of peptides, and R2, R3, R4 and X are as defined above, with another synthon and then processing the obtained intermediate product along known perse procedures to give a compound of formula (I); or B) reacting an acid of formula (Ill)
wherein the symbols -E-, - - - YJ and
R, are as defined above, or a salt thereof, with a halide of formula (IV)
wherein
Z is chlorine, bromine or fluorine and R2, R3, R4 and X are as defined above; and, if desired, converting a compound of formula (I) into another compound of formula (I); and/or if desired converting a compound of formula (I) into a salt thereof; and/or, if desired obtaining a free compound of formula (I) from a salt thereof; and/or, if desired, separating a mixture of isomers of formula (I) into the single isomers.
The compounds of formula (I) can be converted into the corresponding free carboxylic acids by a new process, which is also included in the scope of the present invention.
The second synthon (or building block) used in process A) given above may be any fragment which can be located in the structure of the compound of formula (I) as long as it does not contain the ester group
which is already provided in process A) by the synthon of formula (II). Normally, the product of the reaction between the synthon of formula (II) and the second synthon, will be a compound to be further processed.
The preparation of a synthon of formula (II) comprises reacting a carboxylic acid of formula (V) R6COOH (V) wherein R6 is as defined above, or a salt thereof, with a halide of formula (IV)
wherein
Z, R2, R3, R4 and X are as defined above.
The method, reported above under A), comprises processing the product of formula (II) according to general methods known perse to afford a conventional ester of an acid of formula (III) (e.g., the p nitrobenzyi ester thereof starting from a conventional ester of an acid of formula (V). Among these methods, preferred procedures are those which allow the multistep conversion of an ester of glyoxylic acid, i.e. a compound of formula (V) wherein R6 is HCO; into a penem (see, among others, Woodward et al.,J.Am.Chem.Soc., 101, 6296, 1979).
A number of other procedures are depicted, for example, by R. Bucourt in "Recent Advances in the Chemistry of /3-Lactam Antibiotics", Royal Soc. of Chemistry, Special Publ. no. 38 (1980), 1-25.
According to a preferred procedure of the invention, the carboxylic acid of formula (V) is preferably chosen from the group consisting of tartaric, fumaric and glyoxylic acid.
The reaction between a compound of formula (V), or a salt thereof, and a compound of formula (IV) may be carried out in an inert organic solvent, e.g., dimethylformamide, dimethylsulphoxide, tetrahydrofuran or acetone, at a temperature range between about -700C and about 1 400 C, preferably between about-200C and about 500C. When a compound of formula (V) is used as free acid, the presence of an added organic or inorganic base is usually required.
Suitable organic bases are, for instance, pyridine, lutidine, coilidine or an aliphatic tertiary amine, such as triethylamine or ethyldiisopropylamine; suitable inorganic bases are, for example, alkali metal or alkaline earth hydroxides, e.g., NaOH; carbonates or hydrogen carbonates. Said bases are preferably used in approximately one molar equivalent amount.
Among all the procedures known per se regarding the process reported above under A), a preferred one starts from a compound of formula (II) and leads to a compound of formula (I), wherein the symbol -E- is sulphur and the symbol - - - YJ is
wherein R5 is as defined above.Said preferred procedure comprises
1') oxidizing a compound of formula (II), wherein R6 represents the radical deriving from the
L(+)tartaric acid, to give a compound of formula (II), wherein R6 is formyl;
2') condensing said compound, or a hydrate, an acetal or hemiacetal thereof, with an azetidinone of formula (VI)
wherein R, and B6 are as defined above, to obtain a compound of formula (VII)
wherein
R,, R2, R3, R4, B5 and X are as defined above;
3') converting a compound of formula (VII) into a compound of formula (VIII)
wherein
R,, R2, R3, R4, B5 and X are as defined above and Ph represents phenyl; and
4') cyclizing a compound of formula (VIII) to obtain a compound of formula (I), wherein the symbol -E- represents -S- and the symbol - - - Yv represents
wherein B6 is as defined above.
The step depicted above under 1') may be carried out with a suitable oxidizing agent, e.g., lead tetracetate.
The steps depicted above under 2'), 3') and 4') may be performed according to well known procedures, for example, those reported in our published British Patent Application No. 8005476.
In particular, for instance, step 2') may be carried out A) by heating in an an hydros inert solvent, such as benzene or toluene, with simultaneous azeotropic distillation of the water formed, or B) by treatment with molecular sieves at room temperature, or C) in an aprotic dipolar solvent, such as tetrahydrofuran, in the presence of a basic catalyst such as triethylamine, at a temperature from room temperature to the boiling point of the solvent used.Step 3') may, for instance, be carried out by reacting the compound of formula (VII) with a halogenating agent to give the corresponding halide (preferably halogenation is carried out with thionylchloride to give the chloride), and then reacting the resulting halide with triphenylphosphine, either at room temperature on an inert support, i.e. in the absence of a solvent, or in an inert organic solvent, e.g. dichloromethane, tetrahydrofuran or dioxane, at a temperature from room temperature to about 70"C. Step 4') may, for example, be carried out by heating in an inert solvent, e.g. benzene, toluene, tetrahydrofuran dioxane or dichloromethane, at temperatures varying from about 700C to about 1 500 C, preferably operating under nitrogen atmosphere.
The reaction between a compound of formula (III) and a compound of formula (IV) may be carried out under the same experimental conditions reported above for the reaction between a compound of formula (V) and a compound of formula (IV).
As stated above, a compound of formula (I) may be converted into another compound Qf formula (I), differing in one or both the meanings of R, and Y, to be chosen among the ones already stated.
When a conversion of this type concerns the R, group it may be, for example, the conversion of a protected amino into a free amino, and/or the conversion of a free amino into an acylamino, or a conversion of an alkyl group carrying a protected hydroxy into an alkyl group carrying a free hydroxy substituent. When a conversion of this type concerns the Y radical, it may be, for example, the chemical modification of a substituent in the position 3 of a cephalosporin, or of a 2-thiacephem, or the chemical modification of a substituent in position 2 of a penem, or of a penam.Alternatively, the E and Y radicals may be modified to such a degree to complete, after said conversion, a bicyclic ,B-lactam nucleus different from the starting one, to be chosen between the penicillin, cephalosporin, penem, carbapenem or 1-oxa-1 -dethiacephalosporin classes, a familiar example of this type of conversion being the ring enlargement from a penicillin into a cephalosporin.
Said conversions are processes known perse and may be carried out by analogy with well known procedures, for example under the same experimental conditions already reported in the literature for the conversion of a conventional ester, e.g. p-nitrobenzyi ester, of an acid of formula (III) into the same conventional ester of a different acid of formula (III).
The optional salification of a compound of formula (I) as well as the conversion of a salt into free compound and the separation of a mixture of isomers into the free compound and the may be carried out by conventional methods.
For example the separation of optical isomers may be carried out by salification with an optically active base or acid and by subsequent fractional crystallization of the diastereoisomeric salts following by recovering of the optically active isomeric acids or, respectively, bases. The separation of a mixture of cis- and trans-geometric isomers may be carried out for example by fractional crystallization or by
chromatography.
The preparation of a free acid of formula (III) from an ester of formula (I), which is also included in the scope of the present invention, is performed by cleavage of the ester of formula (I). The cleavage is
preferably carried out by hydrolysis, preferably acid hydrolysis. The acid hydrolysis normally encompasses the use of a variety of Lewis and Bronsted acids, mainly depending upon the group R4
present in the starting ester.
Selected hydrolysis conditions with Bronsted acids include trifluoroacetic acid, diluted in an inert organic solvent or neat (suitable, for example, when R4 is a phenyl ring substituted with electron
withdrawing groups, such as NO2); p-toluenesulphonic acid in benzene (1-2 hours at room temperature are generally enough when R4 is unsubstituted phenyl); formic acid. Weaker inorganic (e.g., boric acid) or carboxylic acids (e.g. citric acid, oxalic acid, acetic acid, phthalic acid), usually dissolved in a mixture of water and an organic solvent, e.g. tetrahydrofuran, are preferably employed with the more sensitive p-lactam substrates.Even a solution of Na2S2Os in a mixture of water and an organic solvent, or a slightly acidic aqueous buffer can be often used when R4 does not contain electron-withdrawing substituents, while esters of formula (I) wherein R4 is a phenyl ring substituted by electron-donating groups (e.g., OCH3) can be cleaved by simple exposure to water. Selected Lewis acids which can mediate the cleavage of esters of formula (I) are, for example, Air13, BF3, ZnBR2, ZnCI2,
SnCI4, FeCI3.They can be used in an inert organic solvent, for example dichloromethane or nitromethane, or in a mixture of organic solvents, usually at a temperature varying from about -200C to about +300 C, preferably around OOC, again the more reactive Lewis acids (e.g., AlCI3) being necessary when R4 contains electron-withdrawing substituents, and less reactive ones (e.g., ZnCI2) being preferred otherwise. In the particular instance of R4 representing o- or p-nitrophenyl, cleavage of the ester may be mediated by chemical (e.g., NH4Cl/iron powder) or catalytic reduction (e.g., hydrogen/Pd on charcoal), since the cleavage of the intermediate esters of formula (I) wherein R4 iso- or p-aminophenyl is even easier.
Halides of formula (IV) may be prepared by addition of an acid of formula HZ,, wherein Z is as above defined, to a vinyl ether/thioether of formula (IX)
wherein R2, R3, R4 and X are as above defined. Said reaction may be performed in or without the presence of an inert, dry organic solvent, such as, for example, tetrahydrofuran, preferably in the absence of water or a moisture, and at a temperature range between about -500C and about +500 C, preferably between about -1 50C and about +300 C.
Compounds of formula (IX) are known compounds or may be prepared starting from known compounds according to general methods.
Selected typical methods include the addition of a phenol/thiophenol to an alkyne (see, for example, W. Reppe et al., Annaien der Chemie 601, 81, 1965); the reaction of a vinyl halide (e.g., vinyl chloride) or of a vinyl ester (e.g., vinyl acetate) with a phenol/thiophenol; the reaction of an alkyl-aryl ether/thioether, substituted on position 2 of the alkyl chain with a suitable leaving group (e.g., a halide, a mesyloxy group), with a base (see, among others, W. M. Lauer and M. A. Spielman, J. Am. Chem.
Soc., 55, 1572, 1933).
Compounds of formula (III), (V) and (Vl) are known compounds or may be prepared by known methods from known compounds.
The invention provides also compounds having formula (II)
wherein
R6 is a radical deriving from an (x-aminoacid, an c-hydroxyacid, an a-ketoacid, or an a-alkenoic acid, wherein the amino, hydroxy and keto groups are either free or protected with a protective group in current use in the field of peptides and R2, R3, R4 and X are as defined above.
Preferred compounds of formula (II) are those wherein
R2 and R3 are hydrogen;
R4 is phenyl, p-nitrophenyl, p-chlorophenyl, p-aminophenyl, p-toiyl, p-tert-butylphenyl, pacetamidophenyl;
X is oxygen;
R6 is the radical deriving from the tartaric or fumaric or glyoxylic acid.
The invention provides also compounds having formula (VII)
wherein R1,R2,R3, R4, R6 and X are as defined above.
The invention provides also compounds having formula (VIII)
wherein R1,R2,R3, R4, R6, X and Ph are as defined above.
Particularly preferred compounds of formula (VII) and (VIII) are those wherein
R1 is ethyl or 1-hydroxyethyl; R2 and R3 are hydrogen;
X is oxygen;
R4 is phenyl, p-nitrophenyl, p-chlorophenyl, p-aminophenyl, p-tolyl, p-tert-butylphenyl, pacetamidophenyl; P6 is acetoxymethyl, carbamoyloxymethyl, (l-methyl-l ,2,3,4-tetrazol-5-yl)-thiomethyl, [1-(2dimethylami no)-ethyl- 1 ,2,3,4-tetrazol-5-yl]-th iomethyl, (1 -carboxymethyl- 1,2 ,3,4-tetrazol-5-yl)- thiomethyl, [1 -(2-carboxy)-ethyl-1 ,2,3,4-tetrazol- 5-yl]-th iomethyl, 2-(2-methyl-5-oxo-6-hydroxy-2, 5- dihydro-1 ,2 ,4-triazin-3-yl)-thiomethyl.
As stated above, the compounds of formula (I), besides being useful in various chemical processes as reported before, can be easily hydrolyzed to give the free carboxylic acids of formula (III) reported above. As already said, the acids of formula (III), and their pharmaceutically or veterinarily acceptable salts, are provided with high, broad-spectrum antibacterial activity against most of Grampositive and Gram-negative bacteria, both in animals and in humans, and are therefore useful in the treatment of the infections caused by said microorganisms to humans and animals, such as respiratory tract infections, e.g. bronchitis, bronchopneumonia, pleurisy; hepatobiliary and abdominal infections, e.g. pyelonephritis, cystitis; obstetrical and gynecological infections, e.g. cervicitis, endometritis; ear nose and throat infections, e.g. otitis, sinusitis, parotitis.
The invention provides also, as useful compounds owning antibacterial activity, compounds of the following formula (la)
wherein P 1,-E-and the symboI---YJ are as defined above; R'2 and R'3 are both hydrogen; X' is oxygen; and R'4 is phenyl, 4-methylphenyl, 4-chlorophenyl, 4-acetamidophenyl and 4-methoxyphenyl, and the pharmaceutically or veterinarily acceptable salts thereof, as well as the pharmaceutical or veterinary compositions containing a compound of formula (la) or a salt thereof as the active principle.
The toxicity of the compounds of formula (la) was found to be similar to that of the corresponding free carboxylic acids of formula (III), and therefore they can be safely used in therapy.
The compounds of formula (la) can be administered to mammals at dosage levels similar to those adopted for the corresponding free carboxylic acids of formula (III). The compounds of formula (la) are preferably administered orally, although they may be administered also in other conventional ways, for example parenterally, e.g. by intramuscular or intravenous injections, or by rectal way. When the compounds of formula (la) are, for example, penems, the dosage levels for the oral administration in adult humans range from about 100 mg to about 200 mg per dose, 1 to 4 times a day, the exact dosage level depending on the age, weight and conditions of the patient.
As stated above, the scope of the invention includes also a pharmaceutical or veterinary composition comprising a compound of formula (la) or a salt thereof in association with a pharmaceutically or veterinarily acceptable excipient (which can be a carrier or diluent).
The pharmaceutical or veterinary compositions containing the compounds of formula (la) or a salt thereof are usually prepared by following conventional methods and are administered in a pharmaceutically or veterinary suitable form.
The pharmaceutical forms used for the oral administration may be, for example, tablets, capsules, sugar or film coated tablets, liquid dispersions. The pharmaceutical forms used for the parenteral, e.g.
intramuscular or intravenous administration may be, for example solutions or suspensions: for intramuscular injections suspensions or solutions, for intravenous injections aqueous solutions may be used.
The pharmaceutical forms used for the rectal administration may be, for example, suppositories.
The pharmaceutical forms contain the compounds of formula (la) and a pharmaceutically acceptable carrier and/or a pharmaceutical acceptable diluent.
The solid oral forms may contain, together with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch and potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethyl cellulose, polyvinyl pyrrolidone; disaggregating agents, e.g. a starch or alginic acid. The liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
The suspensions or solutions for intramuscular injections may contain together with the active compound a pharmaceutically acceptable carrier, e.g. sterile isotonic water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin. The following Examples illustrate but don't limit the invention.
Example 1 1 -Phenoxy-1 -chloro-ethane
Anhydrous hydrogen chloride was passed through neat phenylvinyl-ether (26.5 g, 0.22 mol) at OOC under stirring until the theoretical amount was adsorbed (approx. 8 g). The mixture was purged
with nitrogen, and the obtained product (34.3 g) was used as such for the following step.
NMR bppm (CDCl3) 1.88 (3H, d, J=5.5 Hz, CH-CH3) 6.08 (1 H, q, J=5.5 Hz, CH-CH3) 6.8-7.4 (5H, m, Ar)
Example 2 1-Phenoxyethyl tartrate
A solution of L(+) tartaric acid (16.1 g, 0.11 mol) and triethylamine (30.8 cc, 0.22 mol) in DMF (120 cc) was added dropwise in thirty minutes to an ice-cooled solution of 1-chloro-1-phenoxyethane (34.5 g, 0.22 mol) in DMF (80 cc).
A white precipitate formed in a few minutes.
After one hour the reaction mixture was poured into ice-water (1:1, 500 g) with stirring, and then extracted three times with diethyl ether (3x200 cc).
The combined organic phase was washed with 4% aqueous NaHCO3, brine, dried over Na2 SO4, filtered and evaporated, to give the title compound as a light yellow oil (42 g, 98%).
IR Vmax (CHCI3) 3450, 3060, 2970, 2930, 1740, 1590, 1490, 1115 cm- NMR #ppm (CDCl3) 1.62 and 1.64 (6H, each d, CH-CK3 and COOCH(Ph)CH3) 4.43, 4.45, 4.59 and 4.60 (2H, each s, CH-OH) 6.53, 6.54, 6.62 and 6.64 (2H, each q, CK-CH3) 6.8-7.26 (10H, m, Ar)
Example 3 1-Phenoxyethyl glyoxylate (hydrate)
Lead tetraacetate (46.1 g, 0.104 mol) was added portionwise under nitrogen to an ice-cold, stirred solution of 1 -phenoxyethyl tartrate (38.3 g, 0.098 mol) in anhydrous tetrahydrofurn (250 ml).
A white precipitate formed immediately.
After one hour, the precipitate was filtered off and the filtrate was evaporated to give a brown oil which was dissolved in diethyl ether, sequentially washed with 4% aqueous NaHCO3 and brine, dried (Na2SO4), decolorized with charcoal and filtered over celite.
The filtrate was concentrated in vacuo to give a white slurry, which afforded the pure product upon crystallization from di-isopropyl ether; white crystals, m.p. 95-60C (26.2 g,63%).
IR Vmax (CHCl3) 3540, 1745 cm-1
NMR #ppm (CDCljCD3COCD3) 1.65 (3H, d, J=5.5 Hz, CH-CH3) 5.23 (1 H, dd, J=6.0 and 7.5 Hz, CH(OH)2-) 5.52 (2H, m, exch. D2O, CH(OH)2)
6.58 (1 H, q, CH-CH3) 6.93-7.44 (5H, m, Ar)
Example 4 1-Phenoxyethyl fumarate
A solution of fumaric acid (8.7 g, 75 mmol) and triethylamine (21 ml, 150 mol) in dry dimethylformamide (30 ml) was treated at 0--10 C under stirring with a solution of 1 -phenoxy-1 - chloroethane (23.3 g, 1 50 mmol) in the same solvent (30 mi).
The reaction mixture was kept overnight in the refrigerator, after which time was poured into icewater (200 ml) and extracted with ethyl ether. Evaporation of the solvent left the crude product which was crystallized from ethyl ether-light petrol to give white crystals, m.p. 87-880C (16.1 g,60%).
NMR #ppm (CDCI3)
1.60 (6H, d, J=5.5 Hz, CH-CH3) 6.55 (2H, q, J=5.5 Hz, CK-CH3) 6.7-7.3 (12H, m, vinyl and aryl protons)
Example 5 1-Phenoxyethyl glyoxylate
A stream of ozone in dry oxygen was passed through a solution of 1-phenoxyethyl fumarate (0.6 g) in dichloromethane (20 ml) until a deep blue colour developed.
The solution was purged with nitrogen, and silica gel (2 g) was added. The mixture was let rise to room temperature under vigorous stirring and filtered after one hour. The filtrate was washed with dilute aqueous sodium hydrogen carbonate, dried (Na2SO4) and evaporated, so obtaining the title product, identical with the sample described in Example 3.
Example 6 1-Phenoxyethyl 6-phenoxyacetamidopenicillanate
Triethylamine (200 y1,1.43 mmol) was added to a solution of Penicillin V (500 mg, 1.43 mmol) in tetrahydrofuran (5 ml).
To this solution, 1 -phenoxy-1 -chloroethane (235 mg, 1.5 mmol) in acetonitrile (2 ml) was added at 0 C under stirring. After one hour at OOC the reaction mixture was partitioned between ethyl ether and 4% aqueous NaHCO3. Evaporation of the solvents from the dried (Na2SO4) organic layer left a syrup which was crystallized once from diisopropylether, thus obtaining the title product as a slightly waxy solid in almost quantitative yield.
NMR otppm (CDCl3) 1.29, 1.44, 1.50 and 1.57 (6H, each s, gem-CH3)
1.68 (3H, d, J=5.5 Hz, CH-CH3) 4.39 and 4.43 (1H, each s, N-CH-CO) 4.53 (2H, s, OCH2-C0) 5.45-5.8 (2H, m, p-iactam protons)
6.63 (1H, m, CH-CH3) 6.76-7.40 (11 H, m, CONH and Ar)
Example 7 6-Phenoxyacetamidopenicillanic acid
A mixture of 1 1-hydroxyethyl 6 phenoxyacetamidopenicillanate (50 mg) and ZnCI2 (58 mg) in dry, ethanol-free dichloromethane was stirred 30 min at room temperature.Ethyl acetate and 5% aqueous citric acid were then added and the organic layer was washed several times with brine, dried (Na2SO4), filtered over Hi-flow and evaporated, thus obtaining the anticipated Pencillin V as a white foam in almost quantitative yield.
Example 8 1-Phenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate
A solution of 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylic acid (1.04 g, 3 mmol) and triethylamine (0.42 ml, 3 mmol) in cold (OOC) acetonitrile (5 ml) was added to a stirred solution of 1 chloro-1-phenoxyethane (0.47 g, 3 mmol) in the same solvent.
A white precipitate immediately formed.
After 1 hour at OOC, the reaction mixture was poured into ice-water and extracted with ethyl ether (2x50 ml). The organic extracts were dreid (Na2SO4) and evaporated to give the crude product as a solid in quantitative yield. An analitical sample- was obtained by crystallization from ethyl ether; m.p.
9O0C.
IRvrn8x(KBr)3430-327O, 1780. 1715, 1650, 1600, 1580 and 1525 cm- NMR Gppm (CDCI3)
1.71 (3H, d, J=5 Hz, CH-CH3) 2.03 (3H, br s, 3-CH3) 3.33 (2H, ABq, J=1 8 Hz, separation of inner lines 14 Hz, 2-CH2) 4.55 (2H, s, O--CH,CO) 4.98 (1 H, d, J=6 Hz, 6-H) 5.87 (1 H, dd, J=6 and 9 Hz, 7-H) 6.69 (1 H, q, J=5 Hz, CH-CH3) 6.8-7.4(11 H, m, CONH and Ar)
Example 9 7-Phenoxyacetamido-3-methyl-3-cephem-4-carboxylic acid
Procedure a) 1-Phenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate (50 mg) was dissolved in 3.5 ml of a 20% trifluoroacetic acid solution in dry dichloromethane.
The mixture was stirred for 1 hour at --1 OOC.
Work-up (evaporation to dryness, partition of the residue between ethyl acetate and diluted aqueous NaHCO3 solution, acidification of the latter and back-extraction with ethyl acetate) afforded the title product in almost quantitative yield.
Procedure b)
The 1-phenoxyethyl ester (48 mg) was dissolved in dry benzene (3 ml) and stirred for 1.5 hours at room temperature with a molar equivalent amount of p-toluenesulphonic acid (10 mg), after which time t.l.c. showed complete conversion. The mixture was filtered to collect a powder, 37 mg (quantitative yield), identical by t.l.c. with an authentic sample of the title product.
Procedure c)
1-Phenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate (50 mg) in dry dichloromethane (2 ml) was stirred with ZnCI2 (58.2 mg) for 15 min at room temperature, after which time t.l.c. showed complete conversion. The reaction mixture was taken up in ethyl acetate, washed with diluted HCI solution, dried (Na2SO4) and evaporated to afford the title product.
Procedure d)
The 1-phenoxyethyl ester (50 mg) in dimethylformamide (1 ml) was treated with 0.1 M aqueous Na2S2O5 (1 ml).
After 1 6 hours stirring at room temperature, conversion to the title product was about 5%. Acetic acid (1 ml) was then added, the conversion rose to 4550% after 24 hours.
When 0.1 ml H3PO4 85% was added, 80-85% conversion to the title product was observed by t.l.c. monitoring within 2 hours.
Example 10 3(S)-[1 -(R)-tert-butyidimethylsilyoxyethyl]-4(R)-(1 1-methyl-1,2,3,4-tetrazol-5-yl)-thioacetylthio- 1 -[1 -hydroxy-1 -(1 -phenoxyethyl) oxycarbonyl]-methyl-azetidin-2-one
Step a)
Bromoacetic acid (13.9 g, O.1 mol) and sodium hydrogen carbonate (8.4 g, 0.1 mol) in water (100 ml) were added to 1-methyl-5-mercapto-tetrazole sodium salt (17.14 g, (0.1 mol) in 95% ethanol (100 ml), and the resulting mixture was stirred for 2 hours at room temperature. The organic solvent was removed in vacuo, the resulting aqueous solution was made acid with 2N HCI, saturated with NaCI and extracted several times with ethyl acetate.The combined extracts were dried (Na2SO4) and evaporated to a slurry which crystallized from di-isopropyl ether, thus yielding 16.4 g (94%) of (1 methyl-1,2,3,4-tetrazol-5-yl)-thioacetic acid as white crystals, m.p. 11 20C.
NMR Gppm (d6-acetone) 4.03 (3H, S, CH3)
4.19 (2H, s, CH2) 10.70 H, s, exch. D2O,OH) Step b)
A solution of the product from step a), 6.97 g, 0.04 mol) and triethylamine (0.56 ml, 0.04 mol) in dry dichloromethane (200 ml) was stirred for 5 min at OOC, after which time PCl5 (8.33 g, 0.04 mol) was added portionwise.After 30 min stirring at OOC and an additional hour at room temperature, the mixture was evaporated to dryness in vacuo, taken up in dichloromethane (60 ml), filtered from the insolubie materials, and added dropwise to a solution of pyridine (12.9 ml. 0.16 mol) in dichloromethane (100 ml) which had been previously saturated with H2S at OOC. The resulting mixture was stirred for 70 min at OOC, then freed from excess H2S by evaporation under vacuum. The residue was dissolved in dichloromethane and sequentially washed with 10% H2SO4 and brine. Removal of the solvent left 7.5 g (quantitative yield) of (1 -methyl-1 ,2,3,4-tetrazol-5-yl)-thioacetic acid.
IR Vmax (Nujol) 2540 and 1690 cm-' NMR Gppm (d6-acetone)
4.01 (3H, s, CH3)
4.44 (2H, s, CH2)
7.57 (1H, s, exch. D2O, SH)
Step c)
A solution of the product from step b), (4.1 g, 21.6 mmol) in 1 N NaOH (21.6 ml, 21.6 mmol) was added dropwise at 0 C to a solution of 3(S)-[1 (R)-tert-butyldimethylsilyloxyethylj-4-(R,S)-acetoxy- azetidin-2-one (4.1 g, 14.3 mmol) in water (40 ml) and acetone (80 ml).
The mixture was stirred for 2 hours at 1 00C, occasionally adding a few drops of 1 N NaOH in order to keep the pH between 7.6 and 7.9. Upon removal of the solvent the aqueous solution was extracted several times with dichloromethane, and the organic extracts were dried (Na2SO4) and evaporated in vacuo. Chromatography of the oily residue (SiO2; EtOAc/C6H12 as eluants) afforded 2.5 g (42%) of (3S)-[ 1 (R)-tert-butyidimethylsilyloxyethyl]-4(R)-(1 1-methyl-1,2,3,4-tetrazol-5-yl)- thioacetylthio-azetidin-2-one as a colourless gum.
IR PmaX (CHCI3) 1775 and 1690 cm-'
NMR Gppm (CDCl3) 0.06 (6H, s, Me2)
0.88 (9H, s, But)
1.20 (3H, d, J=6 Hz, CH3-CH) 3.19 (1 H, dd, J=2.0 and 4.0 Hz, CH-CH-CH) 4.01 (3H, s, N-CH3) 4.25 (1H, m, CH3-CH-CH) 4.39 (2H, s, CH2) 5.34(1 H, d, J=2.0 Hz, CH-CK-S) 6.79 (1H, burs, exch. D2O, NH)
Found: C, 43.32; H, 6.58; N, 1 6.67; S, 1 5.28 C15H27N5O3SiS2requires: C, 43.14; H, 6.52; N, 16.77; S,15.36.
Step d)
A solution of the product from step c), 0.835 g, 2 mmol) and 1 -phenoxyethyl glyoxylafe hydrate (0.764 g, 3.6 mmol) in benzene was refluxed for 7 hours with azeotropic removal of the water formed during the reaction.
Chromatography (SiO2; EtOAc/C6H12 as eluants) of the residue afforded the title compound (mixture of four diastereoisomers) as a white foam (501 mg, 41%).
IR Vmax (CHCl3) 3600-3100, 1765 and 1690 cm-1
NMR Gppm (CDCl3) 0.06 (6H, s, Me2)
0.87 (9H, s, But)
1.13 and 1.18 (3H, each d, CH3-CH-OSi) 1.65 (3H, d, CH3-CH-OPh) 3.00-3.40 (1 H, m, CH-CH-CH) 3.92 (3H, s, N-CH3) 4.10--4.30 (1H, m, CH3-CHOSi).
4.15 and 4.28 (2H, each s, CH2) 4.3-4.6 (1 H, broad s, exch. D2O, CH-OH) 5.20-5.35 (1 H, m, CH-CN-S) 5.40--5.60(1 H, m, CH-OH) 6.30--6.70 (1 H, m, CH3-CH-OPh) 6.80-7.40 (5H, m, Ar)
Example 11 (4R)-(1-methyl-1,2,3,4tetrazol-5-yl) thioacetylthio-(3S)-[(1 R) tert-butyldimethylsilyloxyethyl]-l [1 -chloro-1 -(1 -phenoxethyl) oxycarbonyl] methyl-azetidin-2-one
A stirred solution of (4R)-(1-methyl-1 ,2,3,4-tetrazol-5-yl) thioacetylthio-(3S)-[( 1 R) tertbutyldimethylsilyloxyethyl]- 1-[1-hydroxy-1-(1 -phenoxyethyl) oxycarbonyl] methyl-azetidin-2-one (360 mg; 0.59 mmol) in dry tetrahydrofuran (8 ml) at -350C under nitrogen was sequentially treated with pyridine (0.05 ml; 0.62 mmol) and thionyl chloride (0.043 ml; 0.59 mmol).
A white precipitate formed immediately. After five minutes the reaction mixture was warmed up to OOC, filtered and the solid washed with dry tetrahydrofuran.
The filtrate and the washings were evaporated to dryness in vacuo to give the crude title compound as a light yellow gum (370 mg; 100%).
IR Vmax (CHCI3) 1785, 1700 cm-1
Example 12 (4R)-(1 -methyl-1,2,3,4-tetrazol-5-yl)-thioacetylthio-(3S)-[(1 R)tert-butyldimethylsilyloxyethyl]-1 [1 -triphenylphosphoranyliden-1 -(1 -phenoxyethyl) oxycarbonyl] methyl-azetidin-2-one
To a solution of (4R)-( 1-methyl-i ,2,3,4-tetrazol-5-yl)-thioacetylthio-(3S)-[( 1 R) tert butyldimethylsilyloxyethyl]-1 -[1 -chloro-1 -(1 -phenoxyethyl) oxycarbonyl] methyl azetidin-2-one (360 mg; 0.57 mmol), pyridine (0.046 ml; 0.57 mmol), triphenylphosphine (300 mg; 1.14 mmol) and silica gel (Kieselgel 60, 230--400 mesh; 2.2 g) were added with stirring.The solvent was thoroughly removed in vacuo and the residue was let stand for two hours at room temperature, after which time was put on the top of a silica gel column. Elution with ethyl acetate/cyclohexane mixtures gave the title compound as a white foam (283 mg, 58%).
IRvmax (CHCl3 1755, 1690, 1620 cm-1
Example 13 1 -Phenoxyethyl (5R,6S)-6-[(1 R)-tert-butyldimethylsilyloxyethyl]2-(1 1-methyl-1.2.3 .4-tetrazol-5- yl)-thiomethyl-penem-3-carboxylate
A solution of (4R)-(1-methyl-1 ,2,3,4-tetrazol-5-yl) thioacetylthio-(3S)-[(1 R) tert butyldimethylsilyloxyethyl]-1 -[1 -triphenylphosphoranyliden-1 -(1 -phenoxyethyl) oxyca rbonyl] methylazetidin-2-one (282 mg; 0.33 mmol) in dry toluene (12 ml) was refluxed under nitrogen for three hours.
Removal of the solvent and chromatography on silica gel (ethyi acetate/toiuene mixtures as eluants) afforded the title compound (two diastereo-isomers) as a gum; 120 mg,63%.
UV AmaX (hexane) 334 nm
IR Vmax (CHCl3) 1 790, 1 705 cm-1
NMR #ppm (CDCl3) 0.05 (6H, s, Me2)
0.87 (9H, s, But)
1.19 (3H, d, J=6 Hz, CH3-CH-OSi) 1.68 (3H, d, J=5 Hz, CH3-CH-OPh) 3.68 (1 H, dd, J=2 and 4 Hz, CH-CH-CH) 3.88 (3H, s, N-CH3) 4.21. (1H,m, CH3-CH-OSi) 4.58 and 4.64 (2H, each ABq, J=1 3 Hz, separation of inner lines 14 and 7 Hz)
5.54 (1 H, d, J=2 Hz, CH-CH-S) 6.58 and 6.63 (1H, each q, J=5 Hz, CH3-CH-OPh) 6.90-7.40 (5H, m, Ar)
Found: C, 51.63; H, 6.24; N, 12.08; S, 10.88.
C22H35N6O5SiS2 requires: C, 51.97; H, 6.11; N, 12.12; S, 11.10.
Example 14 1 -Phenoxyethyl (5R,6S)-6-[1 (R)-hydroxyethyl[-2-( 1 -methyl-1 ,2,3,4tetrazol-5-yI)-thiomethyl-3 penem-3-carboxylate
Method A A solution of 1 -phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyldimethylsilyloxyethylj-2-( methyl 1 ,2,3,4-tetrazol-5-yl)-thiomethylpenem-3-carboxylate (22 mg; 0.038 mmol) in tetrahydrofuran (1 ml), water (1 ml) and acetic acid (3 ml) was stirred at 280C for 5 hours.
The mixture was concentrated in vacuo.
Chromatography of the residue on silica gel eluting with ethyl acetate/toluene mixtures afforded first unreacted starting material and then the title compound as a white foam (4.6 mg; 26%).
UV Amax (EtOH 95%)
332 nm
Method B
A solution of the o-silylated penem ester 5 mg; 0.026 mmol) in dry THF (0.5 ml) was treated with tetrabutylammonium fluoride (20.4 mg; 0.078 mmol) at ODC. The resulting mixture was stirred for three hours at room temperature, then poured in water and extracted with ethyl acetate.
The combined organic phase was dried (Na2SO4) and evaporated to give a brown oil.
Chromatography on silica gel eluting with ethyl acetate/cyclohexane mixtures gave the title compound as a light yellow gum. (1.8 mg; 15%).
UV vImax (EtOH 95%)
332 nm
Example 15
Sodium (5R,6S)-6-[1 (R)-hydroxyethyl]-2-( -methyl-l ,2,3,4-tetrazol-5-yl)-thiomethyl-penem-3- carboxylate
Procedure a) A solution of 1 -phenoxyethyl (5R,6s)-6-[ 1 -(R)-tert-butyldimethylsilyloxyethylj-2-( 1 -methyl-1 ,2,3,4- tetrazol-5-yl)-thiomethyl-penem-3-carboxylate (69 mg; 0.12 mmol) in 0.4N aqueous oxalic acid (16 ml) and tetrahydrofuran (6 ml) was stirred for twenty hours at 250C. The mixture was neutralized with
NaHCO3, evaporated to small volume in vacuo and then passed through a reverse phase column, eluting with water, thus obtaining the title compound as an amorphous solid (8 mg; 18%).
Wilmax (H2O) 315 nm
NMR Sppm (D2O)
1.28 (3H, d, J=6.3 Hz)
3.87 (1 H, dd, J=1 .4 and 6.3 Hz) 4.10(3H,s) 4.19 (1H, m)
4.40 (2H, ABq, J=1 6.0 Hz, separation of inner lines 13 Hz) 5.59 (1 H, d, J=1.4 Hz) Procedure b)
The 1-phenoxyethyl penemcarboxylate (22 mg; 0.038 mmol) was dissolved in a 4:2:1 mixture of acetic acid/tetrahydrofuran/water and stirred for 16 hours at room temperature. T.L.C. showed more than 80% conversion. The mixture was made neutral with NaHCO3, concentrated and passed through a reverse-phase column to give the title product in 48% yield.
Example 16 ( + )(3,4-Trans)-4-(1 -methyl-1,2,3,4-tetrazol-5-yl) thioacetylthio-3-ethyl-1 -[1 -hydroxy-1 -(1 phenoxyethyl)-oxyca rbonyl]-methylazetidin-2-one
Step a)
(1-methyl-1,2,3,4-tetrazol-5-yl)-thioacetic thioacid (3 g, 15.8 mmol), prepared as described in
Example 10, steps a-b, was allowed to react with (+)trans 4-acetoxy-3-ethylazetidin-2-one (1.57 g, 10 mmol) and 1 N NaOH (15.8 ml) in water/acetone.
When the starting material had virtually disappeared, the mixture was partitioned between dichloromethane and water, and the organic extracts were evaporated to give a syrup which was purified by silica gel chromatography, thus affording 1.13 g of ()(3,4-trans)-4-(1 -methyl-1,2,3,4- tetrazol-5-yl)-thioacetylthio-3-ethyl-azetidin-2-one as a powder.
NMR #ppm (CDCl3) 1.04 (3H, t, J=5.0 Hz, CH3-CH 2) 1.84 (2H, m, CH3-C112-CH) 3.21 (lH,m, CH2-CH-CH) 4.04 (3H, s, N-CH3) 4.40 (2H, s, CH2-S) 5.05 (1H,d,J=2.0 Hz,CH-CH-S)
7.13 (1H, brs, exch. with D2O, NH)
Found: C, 37.81; H, 4.42; N, 23.89; S, 22.28 C19H13N6O2S requires: C, 37.62; H, 4.56; N, 24.37; S, 22.32 Step b)
A solution of ()(3,4-trans)-4-(1 -methyl-1 ,2,3,4-tetrazol-5-yl)-ThioaceWlthio-3-ethylzetidin-2one (1.1 grand 1-phenoxyethyl glyoxylate hydrate (1 g) in benzene (25 ml) was refluxed for 5 hours in a Dean-Stark apparatus.
Complete removal of the solvent afforded the crude product, which could be isolated pure in 61% yield after silica gel chromatography as a mixture of diastereoisomers.
NMR #ppm (CDCl3) 1.02 (3H, t, CH3-CH2-) 1.67 and 1.73 (3H, each d, O-CH(OPh)CH3) 1.80 (2H, q, CH3CR2-) 3.00-3.40 (1 H, m, CH2-CH-CH) 3.97, 3.98 and 3.99 (3H, each s, N-CH3) 5.21,5.23 and 5.31(1 H, each d, J=2.0 Hz, CH-CH-S) 5.38 (1 H, m, N-Cii-OH) 6.50, 6.62, 6.69 and 6.79 (1 H, each q, OCH(OPh)CH3) 6.90-7.50 (5H, m, Ar)
Example 17 (+ ) 1 -Phenoxyethyl (5,6-trans)-2-(1 1-methyl-1,2,3,4-tetrazol-5-yl)-thiomethyl-6-ethyl-penem-3- carboxylate
The title compound was obtained starting from ()(3,4-trans)-4-( 1-methyl-1,2,3,4-tetrazol-5-yl)- thiomethylthio-3-ethyl-1 -[1 -hydroxy- 1 -(1 -phenoxyethyl) oxyca rbonyl] methyl-azetidin-2-one and following the same experimental procedure described in Examples 11,12 and 13 (step 1,95%; step II, 63%; step 111,70% yield).
UV AmaX (CH3OH) 332 nm
IR vmax (CHCl3) 1785, cm-1
NMR #ppm (CDCl3) 1.05 (3H, t J=7.0 Hz, CH3-CH2) 1.70 (2H, d, J=5.5 Hz, CK3-CH) 1.81 (2H, m, CH3-CH2-CH) 3.84(1 H, m, CH2-CH-CH) 3.91 (3H,s,N-CH3) 4.47-4.82 (2H, each ABq, CH2S)
5.39 and 5.41(1 H, d, J=2 Hz, CH-CK-S) 6.59 and 6.63 (1 H, each q, J=5.5 Hz, OCH(OPh)CH3)
6.90 and 7.40 (5H, m, Ar)
Example 18 (+)Sodium (5,6-trans)-2-(1-methyl-1,2,3,4-tetrazol-5-yl)-thiomethyl-6-ethyl-penem-3- carboxylate
Procedure a) (+)1-Phenoxyethyl (5,6-trans)-2-(1-methyl-1,2,3,4-tetrazol-5-yi)-thiomethyl-6-ethyl-penem-3- carboxylate (44.8 mg; 0.1 mmol) was dissolved in dioxane (3 cc) and treated dropwise with a solution of 0.2N aqueous metabisulfite (3 cc). The mixture was vigorously stirred for 30 hours at 250C.
The solution was concentrated to small volume and the pH adjusted at 7.0.
Chromatography on reverse-phase column, eluting with water, afforded the title compound (Rf=0.32, THF/pH 7.4 1:1 phosphate buffer) as an amorphous solid (19.8 mg; 57%) and some unreacted starting material (5 mg).
UV Imax (H2O)
314 nm
Procedure b)
The 1-phenoxyethyl penem carboxylate was stirred for several hours at room temperature in a mixture of acetic acid-tetrahydrofuran-water (4:2:1).
T.L.C. monitoring. Work-up and purification as described in Example 15 afforded the title compounds.
Example 19 p-Nitrophenyl-vinyl-ether
A mixture of p-nitrophenol (4.17 g, 30 mmol) and vinyl acetate (9 ml) in cyclohexane (9 ml) was stirred for 2 hours at room temperature in the presence of mercuric acetate (0.21 g) and 98% H2SO4 (2 drops). The reaction mixture was poured into ice cold 20% NaOH, and stirred for a few minutes. Ethyl ether was then added; the mixture was stirred again and the unreacted sodium p-nitrophenate was recovered by filtration.
The organic layer was washed several times with water, dried (Na2SO4) and evaporated to give the title product (1-1.5 g).
An analitical sample was obtained by silica gel chromatography as a yellow powder.
ppm ppm (d (d6-acetone) 4.60 (1H, dd, J = 6 and 2 Hz, 4.83 (1H, dd, J = 13 and 2 Hz,
6.84 (1H, dd, J = 13 and 6 Hz,
7.11 and 8.12(4H, each d, J = 9 nz, Ar)
By the same experimental procedure, and starting from the appropriate phenol, the following vinyl esters, among others, were obtained and characterized: :
p-acetamidophenyl-vinyl ether
NMR #ppm (CDCl3) 2.18 (3H, s, CH3) 4.27 (1H, dd, J = 6 and 1.8 Hz, 4.60 (1H, dd, J = 14 and 1.8 Hz,
6.48 (1H, dd, J = 6 and 14 Hz,
6.78 and 7.29 (4H, each d, J = 9 Hz, Ar) p-tert-butylphenyl-vinyl-ether NMR # ppm (CDCl3) 1.28 (9H, s, t-Bu) 4.30 (1H, dd, J = 6 Hz and 1.5 Hz,
4.65 (1H, dd, J = 13 and 1.5 Hz 6.54 (1H, dd, J = 6 and 13 Hz,
6.82 and 7.25 (4H, each d, J = 9 Hz, Ar) p-methoxyphenyl-vinyl-ether NMR Sppm (CDC13) 3.60 (3H, s, OCH3) 4.10 (1H, dd, J = 7 and 2 Hz, 4.52 (1H, cd, J = 14 and 2 Hz, 6.46 (1H, dd, J = 7 and 14 Hz,
6.8 (4H, tr s, Ar) p-chlorophenyl-vinyl-ether NMR # ppm (CDC13) 4.53 (1H, cd, J = 4.9 and 1.8 Hz,
4.87 (1H, rd, J = 12 and 1.8 Hz,
6.60 (1H, dd, J = 12 and 4.5 Hz,
6.91 and 7.26 (AH, each d, J = 9
Example 20 1 -p-Nitrophenoxy-1 -chloroethane n --
Dry hydrogen chloride was passed through a solution of p-nitrophenyl-vinyl-ether (0.42 g, 2.5 mmol) in tetrahydrofuran until T.L.C. (cyclohexane/ethyl acetate 3::1) showed complete conversion into a less mobile material (partial cleavage of the product to p-nitrophenol occurring on the silica gel plate)
Removal of the solvent afforded the product in quantitative yield.
NMR Gppm (CDCl3) 1.91 (3H, d, J=5 Hz, CH--CH3,)
6.45 (1 H, q, J=5 Hz, CH-CH3) 7.17 and 8.11 (4H, each d, J=9 Hz, Ar)
Example 21 1 -p-Chlorophenoxy-1 -chloroethane
By following the experimental procedure described in Example 20 the title compound was obtained.
NMR Sppm (CDCI3)
1.90 (3H, d, J=5 Hz, CH3-CH) 6.1(1 H, q, J=5 Hz, CH-CH3) 6.95 and 7.28 (4H, each d, J=9 Hz, Ar)
Other (substituted)-phenoxy-1 -chloroethanes, among which the p-acetylamino and p-tert-butyi ones, were obtained and immediately used.
Example 22 1 -p-Nitrophenoxyethyl-7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate
A solution of 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylic acid (0.871 g, 2.5 mmol) and triethylamine (0.35 ml, 2.5 mmol) in acetonitrile (8 ml) was added to an ice-cold solution of 1-p nitrobenzyloxy-1-chloroethane (2.5 mmol) in a mixture of dichloromethane (3 ml) and acetonitrile (6 ml). After stirring for 1 5 hours, the mixture was partitioned between ethyl acetate and 8% aqueous
NaHCO3. The dried organic phase was evaporated and the residue crystallized from acetone/ethyl ether/petroleum ether, to obtain 0.74 g of the title ether as a white powder, m.p. 92-1 O60C (diastereoisomeric mixture).
IR Vmax (KBr) 3420, 3280, 1775, 1720, 1685, 1 515, 1345, 1255, 1220, 1110, 1060, 750 and
690cm-1
NMR Sppm (CDCI3) 1.73 (3H, d, CH-CH3) 2.11 (3H,s, :C-CH3) 3.35 (2H, ABq, J=1 8.5 Hz, separation of inner lines 14 Hz, S-CH 2) 4.50 and 4.53 (2H, each s, O-CH2-CO) 4.97 (1 H, d, CH-CH-S) 5.81(1 H, m, NH-CH-CH) 6.6-7.4 (9H, m, Ar, CH-CH3 and CONH) 8.15 (2H, d, Ar) A similar procedure, starting from 7-phenoxyacetamido-3-ethyl-3-cephem-4-carboxylic acid and the appropriate halide, afforded the following esters:: 1 -p-Chlorophenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem 4 carboxylate, m.p. 129- 143 C;
IRvmax(KBr)3410,3260, 1765,1710,1670,1630, 1600,1590,1540,1490, 1240,1215 cm-t NMR Gppm (CDCL3)
1.67 (3H, d, CH-CH3) 2.08 (3H, S, :C-CH3) 3.36 (2H, ABq, J=1 8 Hz, separation of inner lines 14 Hz)
4.55 (2H, s, OCH2CO)
4.77 (1 H, d, J=4.5 Hz, CH-CK-S) 5.84 (1 H, dd, J=4.5 and 8.0 Hz, NH-C,'-CH) 6.66 (1 H, q, CH-CH3) 6.807.40 (1 OH, m, CONH and Ar) 1 -p-Acetam idophenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate, m.p.
156-175 C;
IRmax(KBr)3410,3260, 1770, 1710, 1670, 1600, 1535, 1510, 1490, 1240, cm-1
NMR Gppm (CDCl3) 1.72(3H,d, CH-CH3) 2.12 (3H, s, :C-CH3) 2.15 (3H, s, COCH3) 3.55 (2H, ABq, J=1 4.5 Hz, separation of inner lines 18.0 Hz)
4.58 (2H, s, O-CH2CO) 4.98 (1 H, d, J=4.5 Hz, CH-CH-S)
5.87 (1H, dd J=8.0 and 4.5 Hz, NH-CH-CH) 6.56 (1 H, q, CH-CH3) 6.87--7.35(11H, m, CONH and Ar)
Example 23 1 p-Aminophenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate
A solution of 1 -p-nitrophenoxyethyl 7-phenoxyacetamido-3-methyl-3-cephem-4-carboxylate (51 mg, 0.1 mmol) in dichloromethane (3 ml) was stirred for 15 minutes at room temperature in the presence of zinc dust (100 mg) and acetic acid (5 drops). The metal was filtered off and the solvent removed in vacuo to afford the title product in quantitative yield.
IRvmax(CHCl3)3420, 1785,1720,1690,1625, 1600, 1510and 1490 cm-1
NMR Gppm (CDCl3) 1.64 (3H, d, CH-CH3) 2.03 (3H, s, :C-CH3) 3.22 (2H, ABq, J=1 7 Hz, separation of inner lines 6 Hz, S-CH2) 4.03 (2H, br s, NH2)
4.51 (2H, s, O-CH2-CO) 4.95 (1 H, d, J=4.5 Hz, CH-CH2-S) 5.82 (1H, dd, J=4.5 and 8 Hz, NH-CH-CH) 6.55 (1 H, q, CH-CH3) 6.607.40 (1 OH, m, Ar and CONH)
Example 24 1-Phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyldimethylsilyloxyethyl] 2-p nitrobenzyloxywarbonyloxymethyl-penem-3-carboxylate
Step a)
Glycolic acid (10 g), triethylamine (36.8 ml) and p-nitrobenzylchlorocarbonate (19.8 g) in dichloromethane (100 ml) were allowed to react for 1 hour at room temperature. Work-up, filtration through a short column of silica gel (CH2C12 as eluant) and crystallization from di-isopropylether gave 10.2 g of p-nitrobenzyloxycarbonyloxy acetic acid, m.p. 95-980C.
Step b)
The product from step a), 5.4 g, was dissolved in dichloromethane (140 ml) in the presence of triethylamine (3 ml) and treated at --150C with ethyl chlorocarbonate (2.1 ml).
After 20 minutes at room temperature, the mixture was cooled again, another portion of NEt3 (3 ml) was added, and hydrogen sulphide was bubbled into the solution for 30 minutes at -1 50C.
Work-up, extraction with aqueous NaHCO3 and back-extraction with ethyl acetate after acidification, afforded impure p-nitrobenzyloxycarbonyloxythioacetic acid, which was used as such without further purification.
Step c)
The crude material from step b) was mixed with 3(S)-[1 -(R)-tert-butyldimethylsilyloxyethylj- 4(R,S)-acetoxy-azetidin-2-one (2.81 g) in water/acetone and the pH of the solution was brought to 7.5-8.) by the addition of 1 N NaOH. Work-up and chromatography after 1 hour afforded first some unreacted azetidinone and then 2.6 g of (3S)-[1 (R)-tert-butyldimethylsilyloxyethylj-4(R)-p- nitrobenzyioxyca rbonyloxyacetylthioazetidi n-2-one as a syrup.
Step d)
The material from step c), 700 mg, was refluxed with 1-phenoxyethyl glyoxylate hydrate (600 mg) in benzene, with slow azeotropic removal of the water released (Dean-Stark). After 4 hours the solvent was thoroughly evaporated to give 3(S)-[1 (R)-tert-butyldimethylsilyloxyethylj-4(R)-p- n itrobenzyloxyca rbonyloxyacetylth io- 1 -[1 -hydroxy- 1 1 -(1 -phenoxyethyl)-oxycarbonyl]-methyl-azetidin- 2-one as a mixture of diastereoisomers.
Step e)
1.1 g of the product from step d) was treated with pyridine (0.124 ml) and thionyl chloride (0.102 ml) in dry tetrahydrofuran (1 5 ml) for 30 minutes at OOC. Filtration of the salt (Hiflo bed) and removal of any volatile material afforded crude 3(S)-[1 (R)-tert-butyldimethylsilyloxyethyl]-4(R)-p- nitrobenzyloxyca rbonyloxyacetylthio- 1 -[1 -chloro- 1 -(1 -phenoxyethyl)-oxyca rbonyl]-methyl-azetidin-2- one.
Step f)
The material from step e) was treated with a solution of triphenylphosphine (1 g) and pyridine (0.12 ml) in dry THF.
Silica gel (4.6 g) was added and the solvent removed. After 2 hours standing, the powder was poured on top of a silica gel column. Elution with ethyl acetate/cyclohexane afforded 3(S)-[1 (R)-tertbutyldimethylsilyloxyethylj-4-(R)-p-nitrobenzyloxyca rbonyloxyacetylthio- 1 -[1 -triphenyl phosphoranyliden e-l -( 1 -phenoxyethyl)-oxyca rbonyl]-methyl-azetidin-2-one as a white foam.
Step g)
320 mg of the material from step f) was heated for 4 hours in dry toluene at 95-960C. Removal of the solvent and chromatography afforded the title product (120 mg).
NMR #ppm (CDCl3) 0.06 (6H, s, SiMe2)
0.87 (9H, s, But)
1.22 (3H, d, C113-CHOSi) 1.63 and 1.65 (3H, each d, CH3-CH0CO) 3.69 and 3.71(1 H, each dd, J=2 and 4.5 Hz, CH-CH-CH) 4.22 (1 H, m, CH3-CHOSi-CH) 5.09 and 5.11 (1H, each d, :C-CHH-OCO) 5.26 (2H, s, O-CH2-Ar) 5.51 and 5.51(1 H, each d, ::C-CHH-OCO)
5.59 (1 H, d, J=2 Hz, CH-CH-S) 6.55 and 6.62 (1 H, each q, CH3-CKOC0) 6.84-7.40 (5H, m, OC6H5)
7.50 and 8.20 (4H, each d, J=9 Hz, C6H4NO2)
Example 25 1-Phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyldimethylsilyloxyethyl]-2-hydroxymethyl-penem-3carboxylate
A solution of 1 -phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyldi methylsi lyloxyethylj-2-p- nitrobenzyloxycarbonyloxymethyl-penem-3-carboxylate (120 ml) in ethyl acetate (6 ml) was stirred with 5% Pd/C under hydrogen for 1 hour. The catalyst was filtered off and the solvent removed.
Chromatography of the residue (SiO2, ethyl acetate/cyclohexane) afforded the title product.
UV AmaX (CHCl3) 328 nm (E=6236)
NMR #ppm (CDCI3)
0.06 (6H, s, SiMe2)
0.87 (OH, s, But)
1.20 (3H, d, CH3-CHOSi) 1.62 and 1.64 (3H, each d, CH3-CHOCO) 3.13 (1H,brs,OH) 3.64 and 3.66 (1 H, each dd, CH-CK-CH) 4.19 (11 H, m, CH3-CHOSi-CH) 4.54 and 4.55 (2H, each s, CH2OH) 6.52 and 6.55 (1 H, each q, CH3-CH-0CO) 6.85-7.4 (5H, m, Ar)
Example 26 1 -Phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyldi methylsilyloxyethyl]-2-( 1 -methyl-1 ,2,3,4-tetrazol-5- yl)-thiomethyl-penem-3-carboxylate
A solution of triphenylphosphine (60 mg) and diethylazodicarboxylate (36 ml) in dry tetrahydrofuran (2 ml) was stirred at OOC for 30 minutes and then treated with a solution of 1 phenoxyethyl (5R,6S)-6-[1 (R)-tert-butyidimethylsilyloxyethyl]-2-hydroxymethyl-penem-3-carboxylate (30 mg) and sodium l-methyl-l ,2,3,4-tetrazol-5-thiolate (22 mg) in dry tetrahydrofuran (1 ml). The reaction mixture was fractioned by silica gel chromatography to afford 1 5 mg of the title product, identical by UV, IR and T.L.C. with the material obtained according to Example 14.
Claims (22)
1. A compound of general formula (I)
wherein
R1 is hydrogen, halogen or an organic group;
R2 and R3, being the same or different, are hydrogen or an organic group;
R4 is an aromatic or heteroaromatic, monocyclic or bicyclic ring, unsubstituted or substituted by one or more substituents chosen from: C1-C6 alkyl, C1-C6 alkoxy, formyl, phenyl, phenoxy, C2-C6 alkanoyl, benzoyl, C1-C6 alkoxycarbonyl, amino unsubstituted or substituted by one or two C1-C6 alkyl, formylamino, C2-C6 acylamino, benzoyl-amino, halogen and nitro;
the symbol -E- represents -0--S-or -CH2-; X is oxygen or sulphur; and
the symbol - - - Y represents a group completing, with the group -E- and the fused azetidinone ring, the skeleton of a p-lactam antibiotic and the salts thereof.
2. A compound of formula (I) according to claim 1 wherein:
R1 is hydrogen, chlorine, bromine, amino, phenylacetamido, phenoxyacetamido, 2-amino-2- phenyl-acetamido, 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido, C1-C4 alkyl or 1-hydroxyethyl; R2 and R3, being the same or different are hydrogen or C1-C6 alkyl;
R4 is phenyl, unsubstituted or substituted by 1,2 or 3 substituents chosen from chlorine, nitro, methoxy, C1-C4 alkyl, amino, formamido, C2-C3 alkanoylamino;
X is oxygen; the symbol -E- represents-S-or -0-, wherein, when the symbol -E represents-S-, the symbol -- YJ represents a group chosen from:
wherein R6 is an organic group, and wherein, when the symbol -E- represents -0-, then the symbol Y,,,,) represents
wherein R6 is as defined above; and the salts thereof.
3. A compound of formula (I), according to claim 1, wherc;n: R1 is hydrogen, chlorine, bromine, amino, phenylacetamido, phenoxyacetamido, 2-amino-2- phenyl-acetamido, 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido, C1-C4 alkyl or 1 -hydroxyethyl;
R2 and R3 are hydrogen;
R4 is phenyl, p-nitrophenyl, p-aminophenyl, p-chlorophenyl, p-tolyl, p-tert-butylphenyl, pacetamidophenyl;
X is oxygen; the symbol E represents --SS- or wherein, when the symbol -E- represents-S-, the symbol ~YJ represents a group chosen from:
and wherein, when the symbol -E- represents -0-, the symbol # Yj represents
wherein in both the cases R6 is C1-C4 alkyl unsubstituted or substituted by a substituent chosen from::
a") chlorine or bromine;
b") a C29 alkanoyloxy group;
c") a carbamoyloxy group unsubstituted or substituted by one or two substituents chosen from C1C4 alkyl and phenyl, and
d") a -5-Het group, wherein Het denotes a heteromonocyclic or heterobicyclic ring chosen from the group consisting of thiazole, thiadiazole, tetrazole, triazine and tetrazolo-pyridazine, wherein said ring is in turn unsubstituted or substituted by 1,2 or 3 substituents chosen from cyano, C1-C12 alkyl, amino, bromine, chlorine, hydroxy, C1-C12 alkoxy, formyloxy, C2-C12 acyloxy, carboxy, C1-C12 alkoxycarbonyl, and carbamoyl unsubstituted or substituted by one or two C1-C4 alkyl groups; and the salts thereof.
4. A compound of formula (I), according to claim 1, wherein:
R, is ethyl or 1-hydroxyethyl; R2 and Ra are hydrogen;
R4 is phenyl, p-nitrophenyl, p-aminophenyl, p-chlorophenyl;
X is oxygen;
the symbol -E- is sulphur;
the symbol - - - YJ is a group
wherein R5 is acetoxymethyl, carbamoyloxymethyl, (l-methyl-l ,2,3,4-tetrazol-5-yl)-thiomethyl, (1 carboxymethyl-1 ,2,3,4-tetrazol-5-yl)-thiomethyl, [1 -(2-carboxy)ethyl- 1 ,2,3,4-tetrazol-5-yl]thiomethyl, 2-(2-methyl-5-oxo-6-hydroxy-2,5-dihydro- 1 ,2,4-triazin-3-yl)-thiomethyl, [1 -(2-dimethylamino)-ethyl1,2,3,4-tetrazol-5-yl]-thiomethyl, and the salts thereof.
5. A compound according to claim having the formula (la)
wherein R1, -E- and the symbol ---- Y) are as defined in claim 1, R'2 and R'3 are both hydrogen;
X' is oxygen; and R'4 is phenyl, 4-methylphenyl, 4-chlorophenyl, 4-acetamidophenyl and 4methoxyphenyl, and the pharmaceutically or veterinarily acceptable salts thereof.
6. A process for the preparation of a compound of formula (I) as claimed in claim 1, said process comprising:
A) joining a synthon of formula (II)
wherein
R6 is a radical deriving from an cr-aminoacid, an a-hydroxyacid, an cu-keotacid, or an a-alkenoic acid, wherein the amino, hydroxy and keto groups are either free or protected with a protective group in current use in the field of peptides, and
R2, R3 RA and X are as defined in claim 1, with another synthon, and then processing the obtained intermediate product along known per se procedures; or
B) reacting an acid of formula (III)
wherein the symbols # Y and R, are as defined in claim 1, or a salt thereof, with a halide of formula (IV)
wherein
Z is chlorine, bromine or fluorine and R2, R3, R4 and X are as defined in claim 1; and, if desired, converting a compound of formula (I) into another compound of formula (I); and/or, if desired converting a compound of formula (I) into a salt thereof; and/or if desired obtaining a free compound of formula (I) from a salt thereof; and/or, if desired, separating a mixture of isomers of formula (I) into the single isomers.
7. A process according to claim 6 for the preparation of a compound of formula (I) wherein -Eis sulphur and the symbol - - - YJ is
wherein R6 is as defined in claim 2, 3 or 4, wherein the process A) of claim 6 is carried out by:
1 ') oxidizing a compound of formula (II), wherein R6 represents the radical deriving from the
L(+)tartaric acid, to give a compound of formula (II), wherein R6 is formyl;;
2') condensing said compound, or a hydrate, an acetal or hemiacetal thereof, with an azetidinone of formula (VI)
wherein R, is as defined in claim 1 and R5 is as defined in claim 2, 3 or 4, to obtain a compound of formula (VII)
wherein R1,R2,R3, R4 and X are as defined in claim 1 and R6 is as defined in claim 2, 3 or 4;
3') converting a compound of formula (VII) into a compound of formula (VIII)
wherein R1,R2,R3, R4 and X are as defined in claim 1, R5 is as defined in claim 2, 3 or 4 and Ph represents phenyl; and
4') cyclizing a compound of formula (VIII) to obtain a compound of formula (I), wherein the symbol -E- represents-S-and the symbol # Y# represents
wherein R5 is as defined in claim 2, 3 or 4; and, if desired, converting an obtained compound of formula (I) into another compound of formula (I); and/or, if desired, converting a compound of formula (I) into a salt thereof; and/or, if desired, obtaining a free compound of formula (I) from a salt thereof; and/or, if desired, separating a mixture of isomers of formula (I) into the single isomers.
8. A compound of formula (II)
wherein
R2, R3, R4 and X are as defined in claim 1, and R6 is a radical deriving from an a-amino acid, an ahydroxy acid, an a-keto acid, or an a-alkenoic acid, wherein the amino, hydroxy and keto groups are free or protected.
9. A compound of formula (II), according to claim 8, wherein R2, R3, R4 and X are as defined in claim 3 and R6 is a radical deriving from tartaric acid, fumaric or glyoxylic acid.
10. A compound having the formula (VII) reported above in claim 7, wherein Rr, R2, R3, R4 and X are as defined in claim 7.
11. A compound having the formula (VIII) reported above in claim 7 wherein R1, R2, R3, R4, R6 and
X are as defined in claim 7,
12. A process for the preparation of a compound of formula (III), or a salt thereof
wherein the symbols -E- - - - Y) and R1 are as defined in claim 1, said process comprising the cleavage of an ester of formula (I)
wherein the symbols -E- - - - YE , R1, R" R2, R3, R4 and X are as defined in claim 1.
13. A process for the preparation of a compound of formula (III), according to claim 12, wherein the cleavage of the ester of formula (I) is carried out by hydrolysis.
1 4. A process according to claim 1 3 wherein the hydrolysis is an acid hydrolysis.
15. A process according to claim 14 wherein the acid hydrolysis is carried out by a Lewis or a Brönsted acid.
1 6. A process according to claim 1 5 wherein the Lewis acid is selected from the group consisting of AlCl3, BF3, ZnBr2, ZuCI2, SnCI4 and FeCI3.
17. A process according to claim 15 wherein the Brönsted acid is selected from the group consisting of trifluoroacetic acid, forinic acid, oxalic acid, acetic acid and citric acid.
18. A pharmaceutical or veterinary composition containing a suitable carrier and/or diluent and, as the active principle, a compound having the formula (la) reported above in claim 5 or a pharmaceutically or veterinarily acceptable salt thereof.
19. A compound according to claim 1, 8, 10 or 11 specifically identified herein.
20. A process according to claim 6 substantially as described in any one of Examples 1 to 6, 8, lotto 14,16, 17 and 19to26.
21. A process according to claim 12 substantially as described in any one of Examples 7, 9, 1 5 and 18.
22. A compound of formula (la) or pharmaceutically or veterinarily acceptable salt thereof according to claim 5 for use as an anti-bacterial agent.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8219052 | 1982-07-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8314782D0 GB8314782D0 (en) | 1983-07-06 |
GB2124614A true GB2124614A (en) | 1984-02-22 |
GB2124614B GB2124614B (en) | 1985-10-30 |
Family
ID=10531414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB08314782A Expired GB2124614B (en) | 1982-07-01 | 1983-05-27 | Easily cleavable carboxylic esters and their use in the synthesis of penems and other b-lactam antibiotics |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPS5920286A (en) |
BE (1) | BE897183A (en) |
DE (1) | DE3323117A1 (en) |
GB (1) | GB2124614B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1138333A1 (en) * | 1999-10-12 | 2001-10-04 | Suntory Limited | Medicinal compositions for oral use |
WO2003027208A1 (en) | 2001-09-20 | 2003-04-03 | Nof Corporation | Phosphorus-containing carboxylic acid derivatives, process for preparation thereof, and flame retardants |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03182282A (en) * | 1989-12-12 | 1991-08-08 | Sanko Denshi Kogyo Kk | Signal transmitting device in pachinko (japanese pinball) hall |
US5959316A (en) * | 1998-09-01 | 1999-09-28 | Hewlett-Packard Company | Multiple encapsulation of phosphor-LED devices |
-
1983
- 1983-05-27 GB GB08314782A patent/GB2124614B/en not_active Expired
- 1983-06-27 DE DE19833323117 patent/DE3323117A1/en not_active Withdrawn
- 1983-06-30 JP JP58117205A patent/JPS5920286A/en active Pending
- 1983-06-30 BE BE0/211097A patent/BE897183A/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1138333A1 (en) * | 1999-10-12 | 2001-10-04 | Suntory Limited | Medicinal compositions for oral use |
EP1138333A4 (en) * | 1999-10-12 | 2002-01-02 | Suntory Ltd | Medicinal compositions for oral use |
WO2003027208A1 (en) | 2001-09-20 | 2003-04-03 | Nof Corporation | Phosphorus-containing carboxylic acid derivatives, process for preparation thereof, and flame retardants |
EP1433832A1 (en) * | 2001-09-20 | 2004-06-30 | Nof Corporation | PHOSPHORUS−CONTAINING CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND FLAME RETARDANTS |
EP1433832B1 (en) * | 2001-09-20 | 2013-11-13 | Nof Corporation | Phosphorus-containing carboxylic acid derivatives,process for preparation thereof, and flame retardants |
Also Published As
Publication number | Publication date |
---|---|
GB2124614B (en) | 1985-10-30 |
BE897183A (en) | 1983-10-17 |
GB8314782D0 (en) | 1983-07-06 |
DE3323117A1 (en) | 1984-01-05 |
JPS5920286A (en) | 1984-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0592677B1 (en) | Beta-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF | |
US4560550A (en) | Synergistic compositions containing 6-alkylidene penems and their use | |
DK159448B (en) | METHOD OF ANALOGUE FOR PREPARING PENEMCARBOXYLIC ACIDS OR ESTERS THEREOF | |
FI77661B (en) | FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA 2-OXIARYLPENEMER. | |
US4093626A (en) | β-Lactam antibiotics | |
US4517124A (en) | Process for preparing penem derivatives | |
US4585874A (en) | Process for preparing penem derivatives | |
GB2124614A (en) | Easily cleavable carboxylic esters and their use in the synthesis of penems and other b-lactam antibiotics | |
EP0069378A2 (en) | Antibacterial penem derivatives | |
US4795748A (en) | Antibacterial 7-oxo-4-thia-1-azabicyclo[3,2,0]hept-2-ene derivatives | |
US4407815A (en) | β-Lactam antibacterial compounds, their preparation and pharmaceutical compositions containing them | |
US4387051A (en) | β-Lactam antibiotics, their preparation and their use in pharmaceutical compositions | |
US4647558A (en) | Antibacterial agents, their preparation and use | |
US4849419A (en) | 7-oxo-4-thia-azabicyclo[3,2,0]hept-2-ene derivatives | |
EP0091576B1 (en) | 7-oxo-4-thia-1-azabicyclo(3,2,0)heptane derivatives | |
NZ206893A (en) | Cephalosporin derivatives and pharmaceutical compositions;and 7-amino intermediates | |
EP0099580B1 (en) | New 1-oxa-1-dethia-cephalosporin derivatives | |
GB2104509A (en) | New synthetic route to optically active 2-penem-3-carboxylic acid derivatives | |
JPH1077285A (en) | Novel beta-lactam and its production | |
US4108992A (en) | Cephalosporin analogues and compositions | |
US4835150A (en) | Cephem compounds | |
US4252808A (en) | β-Lactam antibacterial agents, their use in pharmaceutical compositions, the process for their preparation and intermediates for use in that process | |
US4661480A (en) | Formamido oxacephems | |
JPH0328434B2 (en) | ||
WO1984002911A1 (en) | beta-LACTAM ANTIBACTERIAL AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |